UPDATED Mar 27, 2024
Potentially undervalued companies with a strong past performance and robust balance sheet.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
IDR | €19.00 | 2.6% | 52.4% | €3.3b | €20.59 | PE16.1x | E12.9% | 1.3% | Software | ||
CAF | €33.70 | 1.5% | 32.7% | €1.2b | €43.63 | PE12.9x | E19.1% | 3.3% | Capital Goods | ||
ART | €4.86 | 19.7% | 20.3% | €277.5m | €5.22 | PE23x | E28.5% | 0.8% | Capital Goods | ||
RJF | €2.48 | -1.6% | 0.8% | €195.4m | €4.10 | PE20.8x | E46.1% | 1.6% | Pharmaceuticals & Biotech | ||
SQRL | €1.61 | -1.2% | -31.2% | €143.3m | n/a | PE10.2x | E16.1% | n/a | Media | ||
LLYC | €9.00 | -0.6% | -12.6% | €101.7m | n/a | PE13.9x | E17.0% | 1.5% | Media |